retatrutide trial results october 2025 This is exciting. 👀 The TRIUMPH-4 for Lilly's investigational medication were released, showing weight loss of up to 71 lbs (~28%) over 68 weeks in the highest-dose group—far beyond Retatrutide for Weight Loss: What

When taken with high consistency, that average increased to 16.6%, and close to one-third exceeded 20% total loss

However, it acts on a different combination of hormone receptors

Post hoc analysis of the Exenatide- PD trialFactors that predict response

Compounded versions of both active ingredients are available at substantially lower cost through telehealth platforms

An imbalance in the gut microbial community can trigger inflammatory responses and modulate GLP-1 secretion, while GLP-1 itself may influence both immune signaling and microbial composition

Key Takeaways Mazdutide is a dual GLP-1/glucagon agonist: Developed by Innovent Biologics, it activates GLP-1 and glucagon receptors but NOT GIP Tirzepatide is a dual GLP-1/GIP agonist: FDA-approved compound activating different second receptor than Mazdutide Retatrutide is a triple agonist: Activates all three receptors (GLP-1, GIP, and glucagon) for most comprehensive coverage Glucagon receptor activation distinguishes Mazdutide: Different metabolic pathway from Tirzepatide despite both being "dual agonists" Regulatory status differs: Tirzepatide is FDA-approved